论文部分内容阅读
目的:探讨复方参仲口服液抗大鼠骨质疏松的作用。方法:采用连续灌胃14 d维甲酸建立大鼠骨质疏松模型,30 d后处死大鼠,取血液作各项有关的生化指标检查,并取左股骨进行骨密度(BMD)的测定,用右股骨作骨组织形态计量学观察,并与注射苯甲酸雌二醇的阳性对照组及服用复方参仲口服液治疗各组比较。结果:与空白组相比,模型组的大鼠出现明显的骨质疏松,而复方参仲口服液治疗各组对大鼠骨质疏松有明显的拮抗作用;复方参仲口服液可时抗维甲酸的抑制体重的作用,提高大鼠骨干重量及骨密度,改善碱性磷酸酶含量及骨组织形态使骨小梁个数增多。结论:复方参仲口服液能改善维甲酸所致的大鼠骨质疏松。
Objective: To investigate the effect of compound Shenzhong oral liquid on anti-osteoporosis in rats. METHODS: A rat model of osteoporosis was established by continuous intragastric administration for 14 days. After 30 days, the rats were sacrificed. The blood was taken for biochemical tests and the left femur was taken for bone mineral density (BMD) measurement. The right femur was used for histomorphometric observation of bone and compared with the positive control group injected with estradiol benzoate and the treatment with compound Shenzhong oral liquid. RESULTS: Compared with the blank group, rats in the model group showed obvious osteoporosis, while compound Shenzhong oral liquid had obvious antagonistic effect on rat osteoporosis; compound shenzhen oral liquid could be resistant to time. The effect of formic acid in inhibiting body weight, improving bone mass and bone density in rats, improving alkaline phosphatase and bone morphology increased the number of trabecular bone. Conclusion: Compound Shenzhong oral liquid can improve rat osteoporosis induced by retinoic acid.